嵌合抗原受体（chimeric antigen receptor，CAR）T细胞疗法由于肿瘤免疫抑制微环境及抗原表 达异质性，在治疗实体瘤面临许多挑战。伴随着分子生物学发展，分子靶向药物高效低毒，是目前肿瘤治疗 的研究热点，CAR⁃T细胞联合分子靶向治疗有良好前景。本文就其在实体瘤的现状和研究进展进行综述，讨 论了CAR⁃T细胞联合包括靶向细胞质、细胞核、细胞外环境这些不同机制药物治疗实体瘤的关键基本原理、 潜在作用及未来的前景和挑战，旨在探索这种联合治疗让更多的癌症患者获益，为后续临床研究提供依据。

Chimeric antigen receptor（CAR）T cell therapy faces many challenges in the treatment of solid tumors due to the immunosuppressive microenvironment and the heterogeneity of antigen expression. With the devel⁃ opment of molecular biology，molecule⁃targeted drugs with high efficiency and low toxicity have become a research hotspot in therapies for tumors. CAR⁃T cell combined molecule⁃targeted therapies shows an inspiring prospect. This paper reviews the current status and research progress of CAR⁃T cell combined molecule⁃targeted drugs for solid tu⁃ mors，discusses the key basic principles，potential roles，future prospects and challenges of CAR⁃T cells com⁃ bined with those drugs with different mechanisms targeting cytoplasm，nucleus，or extracellular environment in the treatment of solid tumors. It aims at exploring the benefit of this combination therapy for more cancer patients and provides support for subsequent clinical research.